MAYO CLINIC
Mayo Medical Laboratories

TEST DEFINITION

```
8/30/2010
Code   Name
----   --------------------
60529  Warfarin Sensitivity Genotype

  **** End of Name to order code Report ****



MML                                  MML Test setup information

  ORDER      EFF                                                                                  Perform
  CODE       DATE   TC     TITLE          Checking Normals              Print normals (# coded)  Site *
 ------      ----   ----   ----------     ----------------              -----------------------  -------
60529(profile)            Warfarin Sensitivity Genotype
   89033     8/18/2010     Warfarin Sensitivity, Genotype                                        MCR
                    Transport temp : Ambient\Refrig OK\Frozen NO
                    26941    Warfarin Sens Phenotype Interp
                           -  -  -  -  -
                    32183    CYP2C9 Star Alleles/VKORC1 Genotype
                             TEST CODE ALWAYS MESSAGE - [Z32183]
                             Z32183   Initial drug dosing recommendations for this CYP2C9/VKORC1
                                      genotype is available in Table 5 of the drug label, located
                                      online at:
                                      http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/
                                      009218s108lbl.pdf
                                      Numerous drugs have been reported to alter the warfarin
                                      dosing requirements for patients. The warfarin drug
                                      labeling also contains information regarding numerous
                                      potential drug interactions and endogenous factors that
                                      may impact dosing.
                                      For a full description of CYP2C9 alleles, see:
                                      http://www.cypalleles.ki.se/cyp2c9.htm
                           -  -  -  -  -
                    28359    CYP2C9 430C>T(*2)
                           -  -  -  -  -
                    28360    CYP2C9 818delA(*6)
                           -  -  -  -  -
                    28361    CYP2C9 1075A>C(*3)
                           -  -  -  -  -
                    28362    CYP2C9 1076T>C(*4)
                           -  -  -  -  -
```

(continued next page)


```
  ORDER      EFF                                                                    Perform
  CODE       DATE   TC     TITLE          Checking Normals              Print normals (# coded)  Site *
 ------      ----   ----   ----------     ----------------              -----------------------  -------
60529  (continued)
                    28363    CYP2C9 1080C>G(*5)
                           -  -  -  -  -
                    87988    VKORC1 -1639G>A
                           -  -  -  -  -
                    28332    Warfarin Sens Genotype Interp
                           -  -  -  -  -
                    28364    Warfarin Sensitivity Reviewed by
                             TEST CODE ALWAYS MESSAGE - [Z60529,ASR]
                             Z60529   Cytochrome P450 2C9 (CYP2C9) metabolizes warfarin and
                                      Vitamin K Epoxide Reductase Complex, subunit 1 (VKORC1) is
                                      the target of warfarin therapy. The combined genotype can
                                      be used to predict an individual's response to warfarin
                                      therapy. Bidirectional DNA sequence analysis was used to
                                      test for the presence of variants in exons 3, 5, and 7 of
                                      the CYP2C9 gene as well as in VKORC1's distal promoter.
                                      These sequencing reactions detect the presence of CYP2C9
                                      430C>T (*2), 818delA (*6), 1075A>C (*3), 1076T>C (*4),
                                      1080C>G (*5), and VKORC1 -1639G>A.  This sequencing assay
                                      will not detect all the known mutations that result in
                                      decreased or inactive CYP2C9 or VKORC1. Rare polymorphisms
                                      could interfere with test results. Absence of a detectable
                                      gene mutation or polymorphism does not rule out the
                                      possibility that a patient has an intermediate or high
                                      sensitivity phenotype due to the presence of an undetected
                                      polymorphism or due to drug-drug interactions.
                             ASR      This test was developed and its performance characteristics
                                      determined by Laboratory Medicine and Pathology, Mayo
                                      Clinic, Rochester MN. It has not been cleared or approved
                                      by the U.S. Food and Drug Administration.
                           -  -  -  -  -
   87844     8/18/2010     Warfarin Sensitivity Genotyping                                        MCR
                    Transport temp : Ambient\Refrig OK\Frozen NO
                    87844    Sequencing
                           -  -  -  -  -
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
```

*Performing Site Legend

MCR Mayo Clinic Dpt of Lab Med & Pathology LAB DIRECTOR: Franklin R. Cockerill, III, M.D.
200 First Street SW
Rochester, MN 55905

==========
==

*** End of Report ***

MML Messages used as normals

CODE	TEXT

Total of 0 normals codes

*** End of Report ***